迈威生物9MW3811注射液临床试验申请获批

Core Viewpoint - Maiwei Biotech (688062) has received approval from the National Medical Products Administration for the clinical trial of its drug 9MW3811, aimed at treating pathological scars in a Phase II study [1] Company Summary - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, developed independently by Maiwei Biotech [1] - The drug is classified as a Class 1 therapeutic biological product and holds independent intellectual property rights [1]